Two ongoing clinical trials are assessing whether addition of DPP-4 inhibitors on the basis of insulin therapy can help improve the severity of COVID-19 (NCT04341935; NCT04542213), which may also be extended to patients without diabetes mellitus. Here, DPP4 is linked to COVID-19.